More Stories

Informist, Friday, Mar. 6, 2026

 

MUMBAI – Shares of pharmaceutical companies are likely to move in a range next week, even as headline indices are expected to fall further, analysts said. Healthcare-related stocks are not seeing as much selling pressure as other sectors, several of which are under pressure due to the war in West Asia, technical analysts said. Analysts are bullish on the prospects of large-cap companies, which will soon begin rolling out their generic glucagon-like peptide 1 class of drugs in India after the domestic patent for the drug expires on Mar. 21.

 

The launch of Semaglutide will help domestic players' sales in the coming quarters, analysts said. An under-penetrated market and launch preparedness will help these companies, they added. Several pharmaceutical companies already have approvals to launch generic Semaglutide, while others are looking to enter the domestic GLP-1 market.

 

A slump in generic Revlimid sales, which will likely lead to a soft March quarter for these companies, is part of the reason why investors remain cautious around these stocks, analysts said.  More diverse offerings in the US markets will likely help companies recover slightly from the decline in sales, according to analysts. In January, US sales rose due to seasonal demand, with certain products doing better, Nomura said in a research report, citing IQIVIA data.

 

Dr. Reddy's Laboratories' speciality segment grew around 8% on-year in the three months to January, higher than the 7.1% growth in the year-ago period, IQIVIA data showed. The Ilumya drug's sales rose 14% on year and Winlevi's total prescriptions grew 43% on year for the period. Sun Pharmaceutical Industries launched Leqselvi in July and has seen modest traction, with total prescriptions and sales growing more slowly than competing products Litfulo and Olumiant. 

 

Cipla's Albuterol market share increased to around 22% in January, up from 20.7% in December. The company's sales market share in Lanreotide injection declined in January due to supply disruptions. The company's tumour drug has been struggling ever since its partner Pharmathen stopped production following an inspection by the US Food and Drug Administration. 

 

Overall, for the three months ended January, sales increased the most for Zydus and Lupin. Both companies recorded a step-up in market share in generic Myrbetriq and benefited from demand for seasonal products. Lupin also recorded a material step-up in market share for generic Spiriva and generic Risperdal Consta, IQIVIA data showed. 

 

Uncertainty around US import tariff rates has also contributed to some of the caution around pharmaceutical stocks, Mehul Sheth, a research analyst at HDFC Securities, said. However, generic drugs will likely be exempt from these tariffs, and the market expects the generic exemption to continue after the Section 232 investigation concludes in the US.

For the week ended Friday, the Nifty Pharma index closed marginally higher at 22970.20 points, compared with a nearly 3?cline in the Nifty 50. Sun Pharmaceutical, Abbott India, and Lupin rose the most this week, gaining 2–3.5%. Wockhardt, Laurus Labs, and Gland Pharma were the worst hit, declining 5–8% during the period. 

 

Technical analysts said that the sectoral index has been trading within a broad congestion range and is facing multiple resistance zones, not far from its current levels. However, analysts said the pharmaceutical sector has emerged as one of the defensive sectors amid a meltdown in the domestic equity market. The Nifty Pharma index will move in a range of 22100 points to 23500 points over the coming week, Vipin Kumaar, derivatives and technical analyst at Globe Capital Market, said.

 

TOP HEADLINES

 

* Dr Reddy's Andhra unit gets 'voluntary action indicated' tag from US FDA
* US FDA tags Granules India arm's Virginia unit 'no action indicated'
* Aarti Ind to invest INR 2 bln-INR 2.5 bln to set up mfg unit in Gujarat
* Aurobindo Pharma arm Eugia launches Pomalidomide capsules in US market
* Gland Pharma gets tentative US FDA nod for brimonidine tartrate eye solution
* Natco Pharma to launch Pomalidomide capsules for cancer treatment in US mkt
* Biocon invests INR 2 bln in Biocon Pharma, INR 1.15 bln in Biocon Biosphere
* Gland Pharma CEO Shyamakant Giri to step down on Apr 30
* Glenmark Pharma arm gets US FDA final nod for asthma inhaler
* Lupin says Maharashtra GST dept's inspection at registered office concludes
* Dabur to invest INR 600 million for minority stake in RAS Beauty
* Cipla arm sets up subsidiary in Saudi Arabia to make, sell pharma products
* Cipla to form JV with Kemwell Biopharma to make, sell biologics globally
* Emcure Pharma to distribute Roche's nephrology, transplant drugs in India
* GlaxoSmithKline Pharma appoints Ronojit Biswas as CFO for 3 yrs from Apr 1
* GSK Pharma says revenue dept concludes search at co's Mumbai office
* Blue Jet Health starts phase 1 of Andhra mfg unit with INR 10 bln investment
* Caplin Point arm gets US FDA final nod for Desmopressin Acetate injection
* Zydus Life gets final approval from US FDA for Ivermectin, Dapsone tablets
* US FDA issues 4 observations to Aurobindo Pharma arm's mfg unit in Telangana
* Abbott India to distribute Novo Nordisk's semaglutide drug brand in India
* Zydus Life says clinical development of pembrolizumab biosimilar successful

 

The following are the resistance and support levels for key pharmaceutical stocks for next week, as per calculations based on their prices on the National Stock Exchange:

 

Company	Price	Week-on-Week Change in %	Resistance	Support
Abbott India	27325.00	3.00	27841.70	26901.70
Alkem Laboratories	5530.00	(-)1.90	5622.70	5450.70
Aurobindo Pharma	1231.90	0.90	1260.20	1201.00
Biocon	390.70	0.20	398.70	381.80
Cipla	1321.20	(-)2.00	1340.70	1305.30
Divi's Laboratories	6329.00	(-)1.20	6470.30	6244.30
Dr Reddy's Laboratories	1303.80	1.40	1329.30	1278.10
Gland Pharma	1669.00	(-)8.40	1746.80	1625.20
GlaxoSmithKline Pharmaceuticals	2517.30	(-)2.10	2564.00	2447.20
Glenmark Pharmaceuticals	2124.40	(-)0.60	2162.50	2075.30
Granules India	577.10	(-)0.90	595.80	560.50
Ipca Laboratories	1501.90	(-)1.80	1540.60	1461.60
Laurus Labs	1026.20	(-)4.60	1067.10	1001.90
Lupin	2343.80	1.80	2390.70	2301.30
Natco Pharma	1019.70	3.20	1039.80	990.00
Pfizer	4849.50	(-)4.20	4924.20	4769.20
Sanofi India	3783.80	(-)4.60	3854.30	3739.70
Sun Pharmaceutical Industries	1799.40	3.60	1826.10	1758.50
Torrent Pharmaceuticals	4317.80	(-)0.40	4421.70	4235.10
Zydus Lifesciences	913.05	(-)0.90	926.50	899.10
Index	Levels
Nifty Pharma	22970.20	0.10	23247.30	22739.00
Nifty 50	24450.45	(-)2.90	24807.50	24237.20
S&P Bse Sensex	78918.90	(-)2.90	80102.20	78220.50

 

 

End

 

Reported by Eshitva Prakash

Edited by Saji George Titus

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000/+91 (11) 4220-1000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.